Skip to main content
Fig. 7 | Molecular Medicine

Fig. 7

From: Human Breast Carcinoma Cells Express Type II IL-4 Receptors and Are Sensitive to Antitumor Activity of a Chimeric IL-4-Pseudomonas Exotoxin Fusion Protein in vitro and in vivo

Fig. 7

Antitumor activity of IL-4(38-37)-PE38KDEL. Four- to six-week-old nude mice were injected subcutaneously with 3–4 × 106 MDA-MB231 breast tumor cells on day 0. (A) Animals were injected i.t. on days 8, 10 and 12, with varying doses of IL-4(38-37)-PE38KDEL or a fixed dose of anti-Tac-PE38KDEL in 20 µ1 volume in a different area of the tumor on each day of injection. The mice that received 750 µg/kg of IL4(38-37)-PE38KDEL were re-injected i.t. with a dose of 500 µg/kg on days 22, 24 and 26. The legend represents the dosage and number of injections on alternate days. Anti-Tac-immunotoxin (anti-Tac-PE38KDEL) binds to IL-2 receptor α chain and served as a negative control. The data presented are mean ± SD of five animals in each group. (B) Cohorts of five animals were i.p. administered with doses of 50, 100, or 150 μg/kg IL-4(38-37)-PE38KDEL 2 times a day for 5 days, beginning on day 3. In the control animals injected with excipient, the tumor continued to grow to a size of ∼65 mm2 by day 27, when all animals were sacrificed. The data presented are mean ± SEM of 5 animals in each group.

Back to article page

Molecular Medicine

ISSN: 1528-3658